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DON'T BITE THE HAND THAT PROVIDES LIFE-SAVING DRUGS:
APPLICATION OF THE HATCH-WAXMAN AND SHERMAN
ACTS TO THE PHARMACEUTICAL INDUSTRY
AND THE DETRIMENTAL EFFECTS
TO FUTURE INNOVATION IN ORDER TO ACHIEVE CURRENT
SAVINGS FOR CONSUMERS
I. INTRODUCTION
Political pressure to cure an ailing medical system in this country has
driven Congress to focus on the pharmaceutical industry as the main cul-
prit and the target of its reform.' In order to protect its constituency from
the rising cost of prescription drugs, 2 Congress passed the Hatch-Waxman
1. See Promoting Availability of Lower Cost Generic Drugs: Hearings on H.R. 1 and
S. I Before the S. Comm. on the Judiciary, 108th Cong. (2003) [hereinafter Hearings on
Affordable Pharmaceuticals] (statement of Sen. Patrick J. Leahy) ("The Senate has
been struggling with the myriad of issues surrounding Medicare reform, and in-
deed the provision of quality, affordable health care generally, for years."); Legisla-
tive and Regulatory Responses to the FTC Study on Barriers to Entry in the Pharmaceutical
Marketplace: Hearings Before the S. Comm. on the Judiciay, 108th Cong. 1 (2003) [here-
inafter Hearings on FTC Study] (statement of Sen. Orinn G. Hatch ) ("President
Bush deserves credit for encouraging the Congress to act in the best interest of the
public on these matters .... I'm excited at the prospect of finally getting the job
done for our seniors and those who are disabled in our society."); Competition in the
Pharmaceutical Marketplace: Antitrust Implications of Patent Settlements: Hearings Before
the S. Comm. on the Judiciary, 107th Cong. 17 (2001) [hereinafter Hearings on Patent
Settlements] (testimony of Dir. Molly Boast, Bureau of Competition, FTC) ("The
surging cost of prescription drugs is a pressing national issue. Recent reports sug-
gest expenditures for retail outpatient prescription drugs rose in the year 2000 to
$131.9 billion .... The Commission is encouraged that Congress ... ha[s] shown
a strong interest in this issue."); James T. O'Reilly, Prescription Pricing & Monopoly
Extension: Elderly Drug Users Lose the Shell Game of Post-Patent Exclusivity, 29 N. Ky. L.
REV. 413, 418 (2002) ("The electoral campaign polls in 2000, as well as public
opinion polls in 2001, show that many consumers, especially elders, care deeply
about prescription drug pricing and the availability of generics.").
2. See Hearings on FTC Study, supra note 1, at 27 (statement of Timothy J.
Muris, Chairman, FTC) (stating that for sixth consecutive year increase in prescrip-
tion drug spending has exceeded all other health services by wide margin); Hear-
ings on Patent Settlements, supra note 1, at 17 (statement of Dir. Molly Boast) (stating
surging cost of prescription drugs is national crisis with drug costs rising in 2000 to
$131.9 billion, an 18.8% increase from previous year); Yuk Fung Hui, FDA's Pro-
posed Rules on Patent Listing Requirements for New Drug and 30-Month Stays on ANDA
Approval (Proposed Oct. 24, 2002), 12 ANNALS HEALTH L. 325, 325 n.1 (2003) (citing
report in San Jose Mercury News that Medicare spending on drugs will exceed
$400 billion in 2002); Marcy L. Lobanoff, Anti-competitive Agreements Cloaked as "Set-
tlements" Thwart the Purposes of the Hatch-Waxman Act, 50 EMORy L.J. 1331, 1331 n.1
(2001) (citing study that states drug claim expenses to reach fifteen percent of
health plan costs in 2001, up from ten percent in 1995); M. Howard Morse, Settle-
ment of Intellectual Property Disputes in the Pharmaceutical and Medical Device Industry:
Antitrust Rules, 10 GEO. MASON L. REv. 359, 363 (2002) (referring to FTC reports of
increasing drug costs). A study by Health Care Financing Administration, cited by
(591)
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Act (the "Act")3 in 1984 to promote faster entry of generic drugs into the
marketplace. While the Act has been successful in achieving the desired
result,4 the language of the Act has enabled brand-name and generic man-
ufacturers to enter into agreements that potentially delay the entry of ge-
neric drug substitutes and thus violate federal antitrust laws set forth in the
Sherman Act.5 In response, Congress introduced legislation designed to
eliminate these agreements, 6 the U.S. Department of Justice (DOJ) and
the Federal Trade Commission (FTC) have increased their surveillance of
antitrust violations within the pharmaceutical industry7 and courts are be-
the FTC, has shown that prescription drug spending has been increasing by the
rate of 12-19% annually. See id.
3. Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L.
No. 98-417, 98 Stat. 1585 (1984) (codified in relevant part at 21 U.S.C. § 355
(2000)); see also Ann K. Wooster, Annotation, Construction and Application of the
Hatch-Waxman Act, Pub. L. No. 98-417, 98 Stat. 1585 (1984) (Codified as Amended at
21 U.S.C.A. § 355 and 35 US.C.A. § 271(e) (1994), 180 A.L.R. FED. 487, 507-15
(2002) (describing construction and application of Act). For a complete discus-
sion of the Act, see infra notes 46-65 and accompanying text.
4. See CONG. BUDGET OFFICE, How INCREASED COMPETITION FROM GENERIC
DRUGS HAS AFFECTED PRICES AND RETURNS IN THE PHARMACEUTICAL INDUSTRY X
(July 1998) (studying "the increase in competition in the pharmaceutical market
and its effects on the profits of drug manufacturers and the prices paid for pre-
scription drugs"). This study found that in 1984, prior to the passage of the Act,
generic substitutes accounted for only nineteen percent of the market, yet by 1996,
generic drugs accounted for forty-three percent of the market, resulting in savings
to consumers of $8-10 billion in 1994 alone. See id. at ix (reciting findings of
study).
5. For a discussion of the problems caused by the language of the Act, see
infra notes 66-85 and accompanying text.
6. See generally Drug Competition Act of 2003, S. 946, 108th Cong. (2003) ("A
bill to enhance competition for prescription drugs by increasing the ability of the
Department ofJustice and Federal Trade Commission to enforce existing antitrust
laws regarding brand name drugs and generic drugs."); Prescription Drug Fair
Competition Act of 2002, H.R. 5272, 107th Cong. (2002) ("A bill to amend the
Federal Food, Drug, and Cosmetic Act to provide greater access to affordable
pharmaceuticals."); Drug Competition Act of 2001, H.R. 1063, 107th Cong. (2001)
("A bill to enhance competition for prescription drugs by increasing the ability of
the Department ofJustice and Federal Trade Commission to enforce existing anti-
trust laws regarding brand name drugs and generic drugs."); Drug Competition
Act of 2001, S. 754, 107th Cong. (2001) (providing for legislation similar to that of
H.R. 1063).
7. See Hearings on FTC Study, supra note 1, at 77 (statement of Sen. Leahy)
("[I]t was the Federal Trade Commission that played such an important role in
exposing the issues of drug companies paying their generic competitors... not to
enter the marketplace."); FTC, GENERIC DRUG ENTRY PRIOR TO PATENT EXPIRATION:
AN FTC STUDY (July 2002), available at http://www.ftc.gov/os/2002/07/generic-
drugstudy.pdf [hereinafter FTC STUDY] (studying abuses under Hatch-Waxman
Act); Morse, supra note 2, at 359 (stating "FTC has devoted substantial antitrust
enforcement resources" to targeting pharmaceutical industry); Scott P. Perlman &
Jay S. Brown, FC Targets Patent Settlement Agreements: Recent Actions Illustrate Permissi-
ble and Unlawful Deals, NAT'L L.J., Nov. 11, 2002, at CI (discussing interplay be-
tween intellectual property and antitrust concerns within pharmaceutical
industry). The authors state:
[Vol. 49: p. 591
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ing called upon more frequently to rule on the difficult task of analyzing
antitrust violations in the pharmaceutical patent arena.
8
While the involvement of the federal legislature and judiciary is lauda-
ble and the need to protect consumers is obvious, 9 this involvement will
decrease the pharmaceutical industry's investment in new research. 10
These actions are eroding the constitutionally protected rights of patent
holders in the drug market, placing this country's future pipeline to life-
saving drugs in a precarious position.1 ' Without the security of patent
protection to recoup substantial research and development costs, brand-
Since the late 1990s, U.S. antitrust enforcement authorities have greatly
increased their scrutiny of the potential anti-competitive effects of patent
settlements. In 1997, then-Department of Justice Antitrust Division chief
Joel Klein warned of increased DOJ scrutiny and called for legislation
subjecting patent settlement agreements to a reporting regime akin to
Hart-Scott-Rodino premerger notification.
Id. The FFC's study examined conduct of brand-name and generic drug compa-
nies that the FTC had previously investigated under the Act to determine if that
conduct was an isolated occurrence or part a regular pattern of anti-consumer
activity. See FTC STUDY, supra, at i (noting subject of study). The study states:
"Through vigorous enforcement of the antitrust laws, the FTC has taken an active
role in ensuring that consumers benefit from competition in the pharmaceutical
industry." Id.
8. See, e.g., Andrx Pharm., Inc. v. Bioavail Corp., Int'l, 256 F.3d 799 (D.C. Cir.
2001) (holding generic manufacturers have standing to sue under Clayton and
Sherman Acts for alleged collusive agreements between pioneer and other generic
manufacturers); In re Terazosin Hydrochloride Antitrust Litig., 203 F.R.D. 551
(S.D. Fla. 2000) (finding per se antitrust violations), rev'd and remanded sub nom.
Valley Drug Co. v. Geneva Pharms., Inc., 344 F.3d 1294 (11th Cir. 2003); HERBERT
HOVENKAMP, FEDERAL ANTITRUST PoLIcv: THE LAw OF COMPETITION AND ITS PRAC-
TICE § 5.6, at 249-56 (2d ed. 1999) (discussing difficulties courts face in applying
antitrust law to certain business arrangements); Morse, supra note 2, at 399-401
(recounting series of judicial attempts to evaluate antitrust violations in pharma-
ceutical industry); O'Reilly, supra note 1, at 429-30 (noting Bioavail decision has
"opened the door for a substantial amount of litigation . . . based upon antitrust
grounds").
9. See Hearings on Patent Settlements, supra note 1, at 18 (statement of Dir. Molly
Boast) ("Within the next 5 years, patents on brand-name drugs with combined
U.S. sales approaching $20 billion will expire .... The successful entry of generic
version of these drugs should affect dramatically the amount consumers pay for
the drugs they need."); see also Generic Drugs: The Stalling Game, CONSUMER REPS.,
July 2001, at 36 [hereinafter Generic Drugs] (stating that over next five years patents
will expire on twenty-one best-selling drugs in United States with annual sales of
$20 billion).
10. See Hearings on FTC Study, supra note 1, at 66 (statement of Bruce N. Kuh-
lik, Senior Vice President & General Counsel of the Pharmaceutical Research and
Manufacturers of America (PhRMA)) ("Better treatments-and even cures-can
come only from the pharmaceutical research industry, and can come only if patent
incentives are maintained.").
11. See 35 U.S.C. § 154(a)(2) (2000) (granting patent for twenty years). De-
spite the statutorily imposed duration of the patent, provisions in the Act allow
generic manufacturers to infringe on the patent holder by testing the drug with
the specific intention of inventing around the patent to get approval from the
FDA. See 35 U.S.C. § 271 (e)(1) (2000) (stating there is no "infringement to make,
use, offer to sell, or sell . . . a patented invention . . . solely for uses reasonably
2004] NOT'E 593
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name pharmaceuticals will find the prospects of investing in research for a
multitude of potentially life-saving drugs too costly. 12 Care must be taken
by all parties involved not to be overly short-sighted by substituting guaran-
teed future access to life-saving drugs for temporary cost savings to the
current consumer.
This Note analyzes the current tension between patent and antitrust
law, specifically within the pharmaceutical industry in light of In re
Cardizem CD Antitrust Litigation,13 the Sixth Circuit's recent decision adopt-
ing a per se illegality analysis. 14 Part II examines the current and tradi-
tional interplay between antitrust and patent law, 15 the Hatch-Waxman
Act' 6 and the loopholes contained therein. 17 Part III examines the facts
and holdings of the Cardizem CD Litigation and the application of the per se
illegality rule.' 8 Part V discusses the competing policies of pro-consumer-
ism and pro-innovation. 19
II. OVERVIEW OF THE SHERMAN AND HATCH-WAXMAN ACTS
A. Historical Interplay of Antitrust and Patent Law
Since the start of the twenty-first century, patent holders have become
subject to an increasing amount of antitrust scrutiny, yet for a large por-
tion of the country's history patent holders were exempted from the appli-
cation of antitrust laws. The Framers of the Constitution realized the
value of innovation in their new country and placed enough importance
on it to protect it with the language, of the Constitution. 20 It was not until
1890 that Congress enacted the Sherman Act, a comprehensive piece of
related to the development and submission of information under a Federal law
which regulates the manufacture, use, or sale of drugs").
12. See PhRMA, Fact Sheet: Pharmaceutical Patent Incentives, at http://
www.phrma.org/publications/publications/17.06.2003.746.cfm (last visited Jan.
14, 2004) (stating that since passage of Act, which weakened pharmaceutical pat-
ents, innovation has become more difficult for discovering new cures, and risk
associated with developing new drugs demonstrates importance of proper patent
protection).
13. 332 F.3d 896 (6th Cir. 2003).
14. See id. at 906-07 (discussing restraints subjected to per se rule).
15. For a historical explanation of antitrust and patent law, see infra notes 20-
45 and accompanying text.
16. For an overview of the Hatch-Waxman Act, see infra notes 46-65 and ac-
companying text.
17. For an explanation of interpretational problems with the Act, see infra
notes 66-77.
18. For a discussion of the facts and analysis in Cardizem, see infra notes 86-184
and accompanying text.
19. For a discussion of the need for a strong pro-innovation policy, see infra
notes 185-99 and accompanying text.
20. See U.S. CoNsT. art. I, § 8, cl. 8 ("To promote the Progress of Science and
useful Arts, by securing for limited Times to Authors and Inventors the exclusive
Right to their respective Writings and Discoveries."). See generally 35 U.S.C
§§ 1-376 (2000) (providing federal patent law).
[Vol. 49: p. 591
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legislation that delineates U.S. antitrust law. 2 1 Section 1 of the Sherman
Act made it illegal to engage in the restraint of trade or commerce
through contract, combination or conspiracy. 22 Section 2 of the Sherman
Act made it illegal to monopolize or attempt to monopolize trade or com-
merce, either singly or with others. 23 For much of the time period follow-
ing the passage of the Sherman Act-primarily the early twentieth
century-the federal government, including the judiciary, viewed a patent
as a constitutionally mandated monopoly granted to the holder of that
patent; the result being that patent holders were typically exempt from
antitrust scrutiny.
24
The Sherman Act has sparked both considerable debate and general
confusion in its greater than one hundred years of existence. 25 The
"vague and malleable"26 language of the Sherman Act has caused
problems and debates resulting in difficulty for the courts that are ulti-
mately called upon to decide the meaning of the law.2 7 Additionally,
problems of interpretation arose from a failure of legal scholars to discern
the intent of the drafters of the Sherman Act 28 and more specifically,
21. See generally 15 U.S.C. §§ 1-4809 (2000) (providing codification of Sher-
man Act).
22. See id. § 1. Section 1 states:
Every contract, combination in the form of trust, or otherwise, or conspir-
acy, in restraint of trade or commerce among the several States, or with
foreign nations, is hereby declared to be illegal. Every person who shall
make any contract or engage in any combination or conspiracy hereby
declared to be illegal shall be deemed guilty of a felony, and, on convic-
tion thereof, shall be punished by fine not exceeding $10,000,000 if a
corporation, or, if any other person, $350,000, or by imprisonment not
exceeding three years, or by both said punishments, in the discretion of
the court.
Id.
23. See id. § 2. Section two states:
Every person who shall monopolize, or attempt to monopolize, or com-
bine or conspire with any other person or persons, to monopolize any
part of the trade or commerce among the several States, or with foreign
nations, shall be deemed guilty of a felony, and, on conviction thereof,
shall be punished by fine not exceeding $10,000,000 if a corporation, or,
if any other person, $350,000, or by imprisonment not exceeding three
years, or by both said punishments, in the discretion of the court.
Id.
24. See Sheila F. Anthony, Antitrust and Intellectual Property Law: From Adversaries
to Partners, 28 AIPLA Q.J. 1, 5 (2000) ("[F]or a long time, the courts held that the
patent exception was so broad as to immunize from antitrust scrutiny the conduct
of firms holding patents."). The author, Sheila F. Anthony, was a commissioner of
the FTC. See id. (providing biographical information about Commissioner
Anthony).
25. See HOVENKAMP, supra note 8, § 2.1a, at 48 (noting general debate and
argument over concern and intent of Sherman Act framers).
26. Id. at 47.
27. See id. (stating that plain language of statute gives no indication to mean-
ing of phrase).
28. See id. at 48 ("[The Sherman Act's] ambiguous language has produced
considerable scholarly dispute over Congressional intent.").
2004] NOTE
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whom Congress was trying to protect with its passage.29 A final source of
confusion has arisen since the mid-twentieth century due to the height-
ened development of various schools of economic theory;3 0 essentially,
what is known today about the economics of competition and monopoly
3 1
was not available to those who drafted the Sherman Act, making it difficult
to interpret in the context of a modem society.
3 2
As previously stated, patent holders in the early post-Sherman Act era
were traditionally exempt from antitrust scrutiny; however, by the 1950s,
the Supreme Court began to narrow patent holders' immunity.3 3 This
shift began the current trend of recognizing the coexistence of antitrust
and patent law. However, two factors commonly complicate this coexis-
tence: (1) free riding and economies of scale 34 and (2) difficult reconcilia-
tion of the substantial bodies of patent and antitrust law.
3 5
29. See id. at 48, 50-51 (reconciling factual record of United States in 1890
with intent of Sherman Act). There were a variety of legal and economic theories
about the purposes served by the Sherman Act, the segment of the American pop-
ulation protected and the intent of Congress. See id. at 50 (noting existence of
various legal and economic theories). Hovenkamp states that the majority of these
theories, aside from the theory of small firm and farmer lobbying efforts, are in-
consistent with the historical facts of the late nineteenth century. See id. Accord-
ing to Hovenkamp, the most likely reason for the Sherman Act was that Congress
was concerned with the sugar trusts, Standard Oil and Carnegie Steel and passed
the Act to empower small firms and farmers because of a fear of "private bigness."
Id. at 50-51.
30. See id. at 48 (discussing Chicago School antitrust analysis, Public Choice
theory and Pareto-efficiency, as they pertain to Sherman Act).
31. See id. ("Most of the modern welfare economics of competition and mo-
nopoly was developed during the 1930s and after.").
32. See generally id. at 47-58 (explaining development of American antitrust
policy as well as courts', scholars' and enforcement agencies' difficulties with Sher-
man Act and its scope and intent).
33. See Anthony, supra note 24, at 5 (citing United States v. Line Material Co.,
333 U.S. 287 (1948), which struck down patent pooling arrangement for price
fixing). "[T] he possession of a valid patent or patents does not give the patentee
any exemption from the provisions of the Sherman Act beyond the limits of the
patent monopoly." Line Material Co., 333 U.S. at 308.
34. See HOVENKAMP, supra note 8, § 5.5a, at 239 (noting first complicating fac-
tor). Hovenkamp states:
The free rider problem derives from the fact that intellectual property
rights can easily be appropriated if they are not given greater legal protec-
tion than is given to more tangible property rights. If the innovator can-
not effectively exclude others from copying the innovation, then many of
the returns to innovation will be lost and we can expect less innovation to
occur. Economies of scale exist because the costs of duplicating products
or processes protected by intellectual property are so much lower than
the cost of developing them in the first place.
Id.
35. See id. (noting second complicating factor). Hovenkamp states:
The second complicating factor is that patents, as well as copyrights and
trademarks, are governed by detailed federal statutes that create numer-
ous potential conflicts with antitrust policy. As a result, the antitrust laws
and the federal intellectual property laws must be interpreted so as to
accommodate one another.
6
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During the 1970s, in an attempt to continue this trend of coexistence
of patent and antitrust law, the DOJ issued the "Nine No-Nos," a statement
of government policy towards patent rights and antitrust enforcement.
36
This policy was not held in high regard3 7 because it presumed that a pat-
ent ensured monopoly power in its specific market, resulting in antitrust
and patent law becoming more adversarial, rather than complementary. 38
Additionally, since its creation in 1982, there is a concern that the Federal
Circuit could act as an alternative forum to have traditional antitrust dis-
putes resolved. By tying a legitimate antitrust issue with a speculative or
minimal patent claim, a party may appeal to the Federal Circuit, thereby




36. See id. § 5.5c, at 243 n.27 ("The forbidden practices were popularly re-
ferred to as the 'Nine No Nos.'"); Anthony, supra note 24, at 5-6 (elaborating on
conduct that was considered suspect under "Nine No-Nos"). The "Nine No-Nos"
were:
1. Tying the purchase of unpatented materials as a condition of the
license [;]
2. Grantbacks[;]
3. Restricting the right of the purchaser of the product in the resale of
the product[;]
4. Restricting the licensee's ability to deal in products outside the scope
of the patent[;]
5. A licensor's agreement not to grant further licenses[;]
6. Mandatory package licenses[;
7. Royalty provisions not reasonably related to the licensee's sales[;]
8. Restrictions on a licensee's use of a product made by a patented pro-
cess[; and]
9. Minimum resale price provisions for the licensed products.
Hovenkamp, supra note 8, § 5.5c, at 243 n.27.
37. See Anthony, supra note 24, at 5 (referring to "Nine No-Nos" as "a now-
infamous government policy").
38. See id. at 6 (summarizing historic view that antitrust and patent law were
opposing policies and DOJ's position that patents automatically conferred market
power exacerbated that view).
39. Although important, the impact of the Federal Circuit's decisions in the
field of antitrust law is outside the scope of this Note. For a complete discussion of
this topic, see Scott A. Stempel & John F. Terzaken III, Casting a Long IP Shadow
over Antitrust Jurisprudence: The Federal Circuit's Expanding Jurisdictional Reach, 69 AN-
TTTRUST L.J. 711, 711-12 (2002) (describing trend of Federal Circuit to decide ap-
peals of antitrust claims that implicate issues of patent law). According to the
authors:
[TI he Federal Circuit has recently taken a much more expansive view of
the circumstances under which a plaintiffs right to relief necessarily de-
pends on resolution of a substantial question of federal patent law,
thereby defining the appellate path as leading to the Federal Circuit.
This trend, taken together with recent decisions expanding the circum-
stances under which the Federal Circuit will apply its own, rather than
regional circuit, precedent in resolving non-patent issues has potentially
far-reaching consequences for how the apparent tensions between anti-
trust law and the protection of IP rights will be resolved in the courts.
Indeed, these developments have led critics to argue that we are now wit-
7
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In 1995, the DOJ, in conjunction with the FTC, issued the "Antitrust
Guidelines for the Licensing of Intellectual Property" (the "Guide-
lines"). 40 The Guidelines are an attempt to create a more "complemen-
tary approach" between antitrust and patent law.4 1 The government's
active communication with the intellectual property community in shap-
ing the policy renders the Guidelines a more accepted approach to en-
forcement.4 2 The Guidelines take a three-principle approach to patent
rights as they pertain to antitrust enforcement: (1) while the underlying
antitrust principles for patent issues remain the same as those for non-
intellectual property issues, the DOJ and FrC recognize the distinct char-
acteristics of patents and will take their unique circumstances into ac-
count;43 (2) the DOJ and FTC will no longer presume that a patent
confers market power upon the holder;4 4 and (3) the DOJ and FTC will
consider licensing of patent rights to be procompetitive.
45
nessing the realization of the fears expressed by Congress before the Fed-
eral Circuit even heard its first case-a Federal Circuit that would serve as
an alternative forum to influence the interpretation of traditional anti-
trust jurisprudence. Intellectual property owners, on the other hand,
likely applaud the Federal Circuit's double-barreled expansion of its do-
minion over the application of the antitrust laws in this arena as a logical
fulfillment of that court's statutory mandate to bring uniformity to the
interpretation and application of the patent laws.
Id.
40. U.S. DOJ & FTC, ANTITRUST GUIDELINES FOR THE LICENSING OF INTELLEC-
TUAL PROPERTY (Apr. 6, 1995), available at http://.www.usdoj.gov/atr/public/
guidelines/ipguide.htm [hereinafter GUIDELINES] ("These Guidelines state the an-
titrust enforcement policy of the U.S. Department ofJustice and the Federal Trade
Commission . . . with respect to the licensing of intellectual property protected by
patent, copyright, and trade secret law, and of know-how.").
41. See Anthony, supra note 24, at 7 ("The Antitrust Guidelines for the Licensing of
Intellectual Property ... issued jointly by the FTC and DOJ in 1995, describe the
agencies' current complementary approach to applying antitrust principles in
cases involving intellectual property rights."); see also GUIDELINES, supra note 40,
§§ 1.0-2.0, at 1-2 (stating agencies' recognition of rights, benefits and protections
unique to intellectual property).
42. See Anthony, supra note 24, at 7 (stating Commissioner Anthony's grati-
tude to intellectual property bar for assistance rendered to FTC in shaping policy).
43. See GUIDELINES, supra note 40, § 2.1, at 3-4 ("Intellectual property has im-
portant characteristics ... that distinguish it from many other forms of property.
These characteristics can be taken into account by standard antitrust analy-
sis. ... "); see also Anthony, supra note 24, at 8 (summarizing Guidelines approach
in section 2.1).
44. See GUIDELINES, supra note 40, § 2.2, at 4 ("The Agencies will not presume
that a patent ...necessarily confers market power upon its owner."); see also
Anthony, supra note 24, at 8 (regarding approach of Guidelines as refinement
from earlier antitrust policy towards intellectual property).
45. See GUIDELINES, supra note 40, § 2.3, at 5 (stating general approval of li-
censing arrangements as beneficial to consumers and resulting in increase and
promotion of innovation); see also Anthony, supra note 24, at 8 (noting that licens-
ing can allow for beneficial combination of intellectual property, increasing speed
to market while reducing cost).
598 [Vol. 49: p. 591
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B. The Hatch-Waxman Amendments
The Federal Food, Drug, and Cosmetic Act (FDCA)4 6 regulates the
manufacture and distribution of pharmaceutical products in the United
States.47 In 1984, Congress passed the Hatch-Waxman Act (the "Act"),
48
which contained a series of amendments to the FDCA designed to reduce
the burdensome regulatory process for generic drug manufacturers. 49
Congress intended these amendments to hasten the entry of low-cost sub-
stitute drugs into the market,50 while granting patent-based incentives to
brand-name firms to continue the necessary research and development.
5 1
Prior to the passage of the Act, a generic manufacturer of a brand-
name drug would have to undergo the exact same regulatory process as
the manufacturer of the pioneer drug.5 2 The Act short-circuited this pro-
cess by allowing the generic manufacturer to file an Abbreviated New
Drug Application (ANDA),53 which allowed development of the generic
drug to "essentially piggy-back on the pioneer drug's human clinical trials
46. 21 U.S.C. §§ 301-99 (2000).
47. See id. § 331 (stating generally that FDCA regulates food, drugs, devices
and cosmetics delivered or introduced into interstate commerce).
48. Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L.
No. 98-417, 98 Stat. 1585 (1984) (codified in relevant part at 21 U.S.C. § 355
(2000)).
49. See H.R. REp. No. 98-857, pt. 1, at 16 (1984), reprinted in 1984 U.S.C.C.A.N.
2647, 2649 (stating that legislation is "necessary to establish" abbreviated generic
drug approval procedure due to FDA failure to do same).
50. See id. at 16-17 (stating congressional finding that additional human
clinical trials by generic manufacturers as required by current FDCA is considered
wasteful and unnecessary by FDA and that Congress found consumer savings to be
approximately $920 billion over next twelve years); see also Wooster, supra note 3, at
508 (stating congressional approval of Act after deciding that FDCA delayed entry
of generic drugs into market because of "cumbersome drug approval process").
51. See H.R. REP. No. 98-857, pt. 1, at 15 (stating purpose of bill); see also
Wooster, supra note 3, § 2[a], at 508 (stating one of Act's policy goals was induce-
ment to brand-name manufacturers to invest in research and development). Spe-
cifically, the House Report states:
The purpose of Title II of the bill is to create a new incentive for in-
creased expenditures for research and development of certain products
which are subject to premarket government approval. The incentive is
the restoration of some of the time lost on patent life while the product is
awaiting pre-market approval. Under current law, a patent continues to
run while the maker of the product is testing and awaiting approval to
market it.
H.R. RFP. No. 98-857, pt. 1, at 15.
52. See H.R. REP. No. 98-857, pt. 1, at 16 (noting result of 1962 amendments
was that generic drug must meet same requirements as pioneer drug for FDA ap-
proval with exception of abbreviated process for generic copies of pre-1962 ap-
proved drugs).
53. 21 U.S.C. § 355(j) (2000). This subsection is entitled "Abbreviated new
drug applications." Id. Section 355(j)(1) states: "Any person may file with the
Secretary an abbreviated application for the approval of a new drug." Id.
9
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and labeling."54 Part of the ANDA requires the generic manufacturer to
file a certification regarding its knowledge of any patents claiming the
listed drug with the Food and Drug Administration (FDA), the agency that
oversees the drug approval process. 55 A generic manufacturer may make
four types of certification: (1) "that such patent information has not been
filed;"5 6 (2) "that such patent has expired;" 57 (3) "the date on which such
patent will expire; "158 or (4) "that such patent is invalid or will not be in-
fringed by the manufacture, use, or sale of the new drug for which the
application is submitted."
59
Due to the obvious potential for dispute over whether, in fact, the
existing patent is invalid or will not be infringed, the fourth type of certifi-
cation ("Paragraph IV certification") places additional requirements on
and provides potential incentives to the generic manufacturer. 60 After
making a Paragraph IV certification, the generic manufacturer must give
notice to the owner of the disputed patent. 6 1 The patent holder has forty-
54. Wooster, supra note 3, § 2[a], at 508-09 (indicating Act's amendment al-
lowing manufacturers to complete abbreviated new drug application rather than
complete new application).
55. See 21 U.S.C. §355(j) (2) (A) (vii) (requiring applicant to certify to FDA, to
best of applicant's knowledge, new drug's relationship to patents existing for listed
drug upon which applicant is relying).
56. Id. § 355(j) (2) (A) (vii) (I).
57. Id. § 355(j) (2) (A) (vii) (II).
58. Id. § 355(j) (2) (A) (vii) (III).
59. Id. § 355(j)(2)(A)(vii)(IV).
60. See id. § 355(0) (5) (B) (iii) (describing incentives and restrictions of Para-
graph IV). Specifically, section 355(0) (5) (B) (iii) states:
If the applicant made a certification described in subclause (IV) of para-
graph (2) (A) (vii), the approval shall be made effective immediately un-
less an action is brought for infringement of a patent which is the subject
of the certification before the expiration of forty-five days from the date
the notice provided under paragraph (2) (B) (i) is received. If such an
action is brought before the expiration of such days, the approval shall be
made effective upon the expiration of the thirty-month period beginning
on the date of the receipt of the notice provided under paragraph
(2) (B) (i) or such shorter or longer period as the court may order be-
cause either party to the action failed to reasonably cooperate in expedit-
ing the action ....
Id.
61. See id. §355(j)(2)(B) (providing notice requirement). Section 355
(j) (2) (B) states:
(i) An applicant who makes a certification described in subparagraph
(A) (vii) (IV) shall include in the application a statement that the ap-
plicant will give the notice required by clause (ii) to-
(I) each owner of the patent which is the subject of the certification
or the representative of such owner designated to receive such
notice, and
(II) the holder of the approved application under subsection (b) of
this section for the drug which is claimed by the patent or a use
of which is claimed by the patent or the representative of such
holder designated to receive such notice.
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five days from receipt of the notice to institute an action for
infringement.
62
If the patent holder fails to file an infringement action, the generic
manufacturer can obtain a declaratory judgment in the matter that results
in immediate FDA approval of the ANDA.63 If, however, the patent
holder files an action for infringement, the FDA immediately places a
thirty-month stay on the approval pending the outcome of the litigation.
64
Regardless of which event occurs first, resolution of the patent dispute in
favor of the generic drug's manufacturer or expiration of the thirty-month
stay, the FDA will then approve the ANDA.
65
C. The "Loopholes " The Thirty-Month Stay and 180-Day Exclusivity
The imprecise language of the thirty-month stay mandated by the
FDA66 and the 180-day exclusivity grant 67 in the Act created "loopholes"
(ii) The notice referred to in clause (i) shall state that an application,
which contains data from bioavailability or bioequivalence studies,
has been submitted under this subsection for the drug with respect
to which the certification is made to obtain approval to engage in the
commercial manufacture, use, or sale of such drug before the expira-
tion of the patent referred to in the certification. Such notice shall
include a detailed statement of the factual and legal basis of the ap-
plicant's opinion that the patent is not valid or will not be infringed.
Id.
62. See id. § 355(j) (5) (B) (iii) (stating chronology of Paragraph IV certifica-
tion and notice to patent holders to initiate action for infringement).
63. See id. § 355( j)(5)(B)(iii)(III). This section states:
Until the expiration of forty-five days from the date the notice made
under paragraph (2) (B) (i) is received, no action may be brought under
section 2201 of title 28, for a declaratory judgment with respect to the
patent. Any action brought under section 2201 shall be brought in the
judicial district where the defendant has its principal place of business or
a regular and established place of business.
Id.
64. See id. § 355(j) (5) (B) (iii) (stating that if action for infringement is
brought within forty-five days of notice, approval of ANDA is placed on hold for
thirty-month period beginning from date notice was received by FDA).
65. See id. (stating that if action for infringement is brought, approval of
ANDA would occur either at end of mandatory thirty-month stay or whenever
court in infringement action orders).
66. See id. (providing for thirty-month stay). Section 355(j) (5) (B) (iii) states:
If the applicant made a certification described in subclause (IV) of para-
graph (2) (A) (vii), the approval shall be made effective immediately un-
less an action is brought for infringement of a patent which is the subject
of the certification before the expiration of forty-five days from the date
the notice provided under paragraph (2) (B) (i) is received. If such an
action is brought before the expiration of such days, the approval shall be
made effective upon the expiration of the thirty-month period beginning
on the date of the receipt of the notice provided under paragraph
(2) (B) (i) or such shorter or longer period as the court may order ....
Id.
67. See id. § 355(j) (5) (B) (iv) (providing for 180-day exclusivity grant). Sec-
tion 355 0) (5) (B) (iv) states:
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that various parties have exploited, often delaying the arrival of generic
drugs to the market.68 The exclusivity provision gives the first generic
company that files an ANDA challenging a pioneer drug's patent a six-
month period to market its generic drug before competitors' subsequent
ANDA applications are approved for that pioneer drug.69 The exclusivity
period begins to run when the generic manufacturer first markets its drug
after receiving FDA approval of its ANDA.70 Congress included this exclu-
sivity grant in the Act as an incentive to litigate against pioneer drug com-
panies. 71 Without that incentive, a single generic company, the "first-to-
file," would bear all of the risk in challenging the patent holder.72 If the
patent holder brought an unsuccessful cause of action against that generic
company-i.e., the patent was declared invalid-then all subsequent ge-
neric companies could immediately begin marketing without having
borne any risks or costs of litigation. 73 As a consequence of both skillful
If the application contains a certification described in subclause (IV) of
paragraph (2) (A) (vii) and is for -a drug for which a previous application
has been submitted under this subsection continuing such a certification,
the application shall be made effective not earlier than one hundred and
eighty days after-
(I) the date the Secretary receives notice from the applicant under
the previous application of the first commercial marketing of the
drug under the previous application, or
(IH) the date of a decision of a court in an action described in clause
(iii) holding the patent which is the subject of the certification to
be invalid or not infringed, whichever is earlier.
Id.
68. See Hearings on FTC Study, supra note 1 (statement of Timothy J. Muris,
Chairman, FTC) (reporting findings from FTC Study). Chairman Muris informed
the Senate Judiciary Committee that the FFC's study examined 104 brand-name
drugs from 1992 to 2000. See id. Chairman Muris reported the study found eight
brand-name drugs whose manufacturer/patent holder obtained more than one
thirty-month stay, resulting in delays of generic entry anywhere from four to forty
months. See id. With respect to the 180-day period of exclusivity, Chairman Muris
reported the study found fourteen instances where litigation was settled with the
potential to "park" the first generic's exclusivity, thus preventing subsequent ge-
neric entry. See id.
69. See 21 U.S.C. § 3550) (5) (B) (iv) (stating no subsequent ANDA applicant
may receive approval until 180 days after initial applicant's commercial marketing
of drug or favorable court decision).
70. See id. (defining two triggering devices in Act concerning initiation of 180-
day exclusivity period, commercial triggering and court decision triggering).
71. See O'Reilly, supra note 1, at 415-16 ("The six-month reward means the
first-to-file has an incentive to litigate. Only after that 180 days would other ge-
neric copies be permitted to enter the market.").
72. See id. at 420-21 (discussing confusion over which generic manufacturer
would receive exclusivity rights). The "first-to-file" refers to the first generic com-
pany to assert a Paragraph IV certification against a pioneer drug's patent in an
ANDA application. See id. at 415.
73. See id. at 414 (noting that dozens of competing generic manufacturers
would be free riders on first successful challenger to pioneer's patented drug).
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lawyering7 4 and silence in the legislative history of the Act,75 the grantee
and patent holder have used the grant to "blockade" subsequent generic
manufacturers who have filed ANDA applications for the same pioneer
drug.7 6 By not marketing the drug after receiving final approval from the
FDA on its ANDA application, the grantee never triggers the 180-day ex-
clusivity period, thus preventing subsequent generic manufacturers from
receiving final FDA approval to initiate marketing.
77
The thirty-month stay is an action by the FDA, mandated by statute,
that is triggered by the filing of an infringement suit by the patent holder
against the generic manufacturer that filed a Paragraph IV certification in
its ANDA. 7 8 The problem with the stay stems from its application to pat-
ents on the drugs, not the drugs themselves. 79 Pioneer drugs may have
several patents covering them, including protection of their active ingredi-
ent(s), their manufacturing process and their packaging, as well as long-
term improvements made to such drugs.8 0 Therefore, patent holders of
pioneer drugs can institute infringement actions for multiple patents on a
single drug, each qualifying for a thirty-month stay.8 1 Additionally, patent
74. See id. (stating that "skilled Washington D.C. lawyers dreamed" up ways to
have pioneer drug companies pay generic manufacturers to keep its drug off
market).
75. See id. at 416 (referring to lack of explanation or commentary in Act's
legislative history concerning 180-day exclusivity period).
76. See Julia Rosenthal, Hatch-Waxman Use or Abuse? Collusive Settlements Be-
tween Brand-Name and Generic Manufacturers, 17 BERKELEY TECH. L.J. 317, 328 (2002)
(noting that settlement of infringement litigation between pioneer manufacturer
and first generic challenger does not necessarily open generic market).
77. See Morse, supra note 2, at 387 (detailing incentives for pioneer manufac-
turing firms to file patent infringement suits); Rosenthal, supra note 76, at 327-28
(describing loopholes and resulting collusive agreements between first generic
challenger and pioneer manufacturer); see also Hui, supra note 2, at 327 (explain-
ing exposure of loopholes during recent high profile litigation). Where a litiga-
tion settlement contains an agreement that the generic manufacturer will not
market the drug for the duration of its 180-day exclusivity in exchange for com-
pensation from the brand-name drug manufacturer, neither triggering event-i.e.,
the commercial marketing or the court decision finding the patent invalid-oc-
curs. See Lobanoff, supra note 2, at 1343-44 (describing how this type of patent
settlement appears anticompetitive).
78. See 21 U.S.C. § 355(j) (5)(B) (iii) (2000).
79. See id. ("[A] pproval shall be made effective immediately unless an action is
brought for infringement of a patent which is the subject of the certification ... )
(emphasis added).
80. See 35 U.S.C. § 154(a)(1) (2000) (stating protection of patent). Section
154(a) (1) states:
Every patent shall contain a short title of the invention and a grant ... of
the right to exclude others from making, using, offering for sale, or sell-
ing the invention .. . , and, if the invention is a process, of the right to
exclude others from using, offering for sale or selling ... products made
by that process ....
Id.
81. See FTC STUDY, supra note 7, at 39-56 (explaining FDA patent-listing prac-
tices and use of multiple thirty-month stays); Hui, supra note 2, at 327-28 (explain-
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holders can file subsequent patents on the pioneer drug, even after the
generic manufacturer has filed its initial Paragraph IV certification. 82 As a
result of this action, generic manufacturers must re-certify that the pro-
posed generic drug does not infringe on the newly filed patent, causing
another thirty-month stay to be placed on the generic drug if the patent
holder initiates an action for infringement of the new patent.8 3 As long as
litigation continues and a stay is imposed upon the ANDA, the generic
manufacturer remains barred from the market.8 4 The FDA recently en-
acted a rule that will limit each pioneer drug to only one thirty-month stay
under the Act, regardless of the amount of patents covering the drug.
85
The rule, however, is too new to have generated any substantial commen-
tary and will, therefore, be excluded from analysis in this Note.
III. IN RE CARDIZEM CD ANTITRUST LITIGATION
A. Facts Surrounding the Antitrust Claims
Cardizem CD Litigation (used to refer collectively to the series of cases
in In re Cardizem CD Antitrust Litigation)86 involved an agreement (the
"Agreement") between defendant Hoechst Marion Roussel, Inc.
ing how manipulation of FDA's patent-listing procedure can be used to implement
multiple thirty-month stays on single drug.)
82. See FTC STUDY, supra note 7, at iii (noting ability of pioneer manufacturer
to file new patents after generic manufacturer submits ANDA and consequence
that generic manufacturer must re-certify its ANDA for every new patent filed after
ANDA submission).
83. See Hui, supra note 2, at 327 (noting ability of pioneer companies to take
advantage of multiple stays in litigation).
84. See Rosenthal, supra note 76, at 328 (explaining delay tactic employed by
drug companies). Rosenthal explains that "[a]s long as the patent infringement
litigation between the pioneer manufacturer and the first generic challenger is
ongoing.., the generic market is essentially held closed." Id.
85. See Applications for FDA Approval to Market a New Drug: Patent Submis-
sion and Listing Requirements and Application of 30-Month Stays on Approval of
Abbreviated New Drug Applications Certifying That a Patent Claiming a Drug Is
Invalid or Will Not Be Infringed, 68 Fed. Reg. 36,676 (June 18, 2003) (to be codi-
fied at 21 C.F.R. pt. 314). The requirements state that:
The final rule limits to one per ANDA . . . the maximum number of
statutory 30-month stays of approval to which an innovator will be enti-
tled when it submits multiple patents for the same [pioneer drug]. Elimi-
nating multiple 30-month stays will speed up the approval and market
entry of generic drugs. The final rule also clarifies patent submission and
listing requirements, which will reduce confusion and help curb attempts
to take advantage of this process. Specifically, patents claiming packag-
ing, intermediates, or metabolites must not be submitted for listing.
Id.
86. In re Cardizem CD Antitrust Litig. (Cardizem CD III), 332 F.3d 896 (6th
Cir. 2003); In re Cardizem CD Antitrust Litig. (Cardizem CD II), 105 F. Supp. 2d
682 (E.D. Mich. 2000); In re Cardizem CD Antitrust Litig. (Cardizem CD I), 105 F.
Supp. 2d 618 (E.D. Mich. 2000). These cases are collectively referred to as
"Cardizem CD Litigation."
[Vol. 49: p. 591
14
Villanova Law Review, Vol. 49, Iss. 3 [2004], Art. 4
https://digitalcommons.law.villanova.edu/vlr/vol49/iss3/4
("Hoechst"), a brand-name manufacturer of the drug Cardizem CD,8 7 and
defendant Andrx Pharmaceuticals, Inc. ("Andrx"), a potential generic
manufacturer of the drug.8 8 The Agreement delayed Andrx's entry of its
drug into the market.8 9 Also as part of the Agreement, Hoechst was to
make quarterly payments of $10 million to Andrx; in exchange, Andrx was
to keep its generic version of Cardizem CD from entering the marketplace
even though Andrx had received tentative FDA approval. 90 Andrx had
received this tentative approval through a Paragraph IV certification. 9 1
Plaintiffs comprised four separate groups, each asserting similar allega-
tions, but seeking damages under different state and federal antitrust
claims.
92
87. See Cardizem CD I, 105 F. Supp. 2d at 622 (defining Cardizem CD as pre-
scription heart medication consisting of once-daily dose of compound diltiazem
hydrochloride prescribed primarily for treatment of angina, hypertension and
heart-attack and stroke prevention).
88. See Cardizem CD I, 105 F. Supp. 2d at 686-89 (detailing chronology of
events between Andrx and Hoechst with respect to Cardizem CD and Andrx's ge-
neric version, Cartia XT). Essentially, the patent dispute centered on what is
known as a dissolution profile; that is, the percent of the active ingredient dissolv-
ing, or releasing, in the body over a given timeframe, usually eighteen hours. See
id. (describing relevant dissolution profiles for Cardizem CD and Cartia XT).
89. See Cardizem CD III, 332 F.3d at 899-900 (stating fundamental terms of
Agreement as $10 million quarterly payments to Andrx, in exchange for which
Andrx would refrain from marketing Cartia XT, subsequent to FDA approval).
For a complete discussion of the full terms of the Agreement, see Cardizem CD II,
105 F. Supp. 2d at 695-99.
90. See Cardizem CD Ill, 332 F.3d at 899-900 (detailing specific terms of
Agreement).
91. See id. at 902 (recounting approval process undergone by Andrx). Andrx
filed an ANDA on September 22, 1995, seeking approval to market a generic ver-
sion of Cardizem CD. See id. In November 1995, Carderm Capital, L.P., the licen-
sor of Hoechst's Cardizem CD patents, was issued a new patent concerning
Cardizem CD's dissolution profile, which it licensed to Hoechst. See id. On De-
cember 30, 1995, Andrx filed a Paragraph IV certification, claiming Cartia XT did
not infringe on any patents related to Cardizem CD. See id. In January 1996,
Hoechst and Carderm Capital filed a patent infringement suit against Andrx in the
U.S. District Court for the Southern District of Florida, claiming that Cartia XT
infringed on the newly issued patent for Cardizem CD. See id.
92. See Cardizem CD, 105 F. Supp. 2d at 625-27 (defining four groups of plain-
tiffs and their allegations consolidated into single action). The first group of plain-
tiffs were "state law plaintiffs," indirect purchasers (consumers and retail
pharmacies) in several states claiming violations of state consumer-protection and
antitrust statutes and seeking recovery on a common law theory of unjust enrich-
ment. See id. at 625. The second group of plaintiffs was a class-action group com-
prising any persons who directly purchased Cardizem CD from Hoechst any time
after July 9, 1998. See id. at 625-26. They alleged that the Agreement was a hori-
zontal market allocation between competitors to fix and maintain the price of
Cardizem CD in the United States, and as such, was per se illegal under the Sher-
man Act, or alternatively, illegal under the rule of reason analysis. See id. at 626
n.4. The third group of plaintiffs, composed primarily of large retail and super-
market chains, also alleged Sherman Act violations, but remained individual plain-
tiffs not part of the class. See id. at 626-27. This third group's allegations were
similar to the class's except they alleged only a per se illegal arrangement. See id. at
627 n.5. The fourth group consisted of two individual corporations, CVS Merid-
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The defendants sought certification of two questions for interlocutory
appeal to the Sixth Circuit 93 based on the district court's denial of defend-
ants' motion to dismiss all counts in Cardizem CD P4 and its grant of plain-
tiffs' motion for partial summary judgment in Cardizem CD I.9 5  In
affirming both the lower court's rulings,9 6 the Sixth Circuit made the sig-
nificant determination that the Agreement constituted a horizontal mar-
ket allocation and a per se illegal restraint of trade under the Sherman
Act.
9 7
B. Narrative Analysis-Agreement Deemed Presumptively Illegal
By affirming the district court's holding that the Agreement consti-
tuted a per se illegal restraint of trade, the Sixth Circuit effectively barred
the defendants from arguing the procompetitive aspects of the Agree-
ment.98 Initially, the court explored prior Supreme Court holdings under
the Sherman Act to determine whether to analyze the Agreement under
the more common "rule of reason" approach 99 or under the more pre-
ian, Inc. and Rite Aid Corp. These plaintiffs alleged Sherman Act violations, but
were not part of the other two groups of plaintiffs. See id. at 627. Their allegations
were substantively similar to the allegations of the other groups of plaintiffs. See id.
at 627 n.6.
93. See Cardizem CD III, 332 F.3d at 900 (noting certification of appeal). The
Sixth Circuit noted:
[T]he district court certified two questions for interlocutory appeal:
(1) ... In determining whether Plaintiffs properly pled antitrust injury,
does the language of the Sixth Circuit's decisions in Valley Products Co. v.
Landmark and Hodges v. WSM, Inc. require dismissal of Plaintiffs' antitrust
claims at the pleading stage if Plaintiffs cannot allege facts showing that
Defendants' alleged anticompetitive conduct was a "necessary predicate"
to their antitrust injury; i.e., that dismissal is required unless Plaintiffs
plead facts showing that the alleged antitrust injury could not possibly
have occurred absent Defendants' alleged anticompetitive conduct?
(2) ... In determining whether Plaintiffs' motions for partial summary
judgment were properly granted, whether the Defendants' September 24,
1997 Agreement constitutes a restraint of trade that is illegal per se under
section 1 of the Sherman Antitrust Act and under the corresponding
state antitrust laws at issue in this litigation.
Id. (citations omitted).
94. See Cardizem CD I, 105 F. Supp. 2d at 681 (denying all counts of defend-
ants' motions to dismiss).
95. See In re Cardizem CD Antitrust Litig. (Cardizem CD II), 105 F. Supp. 2d
682, 706-07 (E.D. Mich. 2000) (granting plaintiffs' motion for partial summary
judgment that Agreement constituted per se violation of Sherman Act).
96. See Cardizem CD Il, 332 F.3d at 915 (affirming both district court's denial
of motion to dismiss by defendants and grant of partial summary judgment to
plaintiffs that Agreement constituted per se violation of Sherman Act).
97. See id. at 908 (concluding Agreement between competitors was to elimi-
nate competition in United States for Cardizem CD).
98. See id. at 909 ("[T]he law is clear that once it is decided that a restraint is
subject to per se analysis, the claimed . . . presence of procompetitive effects is
irrelevant.").
99. See id. at 906 (citing State Oil Co. v. Kahn, 522 U.S. 3, 10 (1997)). The
court noted that "[m]ost restraints are evaluated using a 'rule of reason.'" Id.
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sumptive per se analysis. 10 Upon subsequent examination of the terms of
the Agreement, the court determined the agreement embodied a "classic
example of a per se illegal restraint of trade."' 0 '
The circuit court faced two questions' 0 2 on interlocutory appeal certi-
fied by the district court pursuant to 28 U.S.C. § 1292(b).10 3 By first de-
ciding which mode of analysis-i.e., the rule of reason or the per se
approach-should be applied to the Agreement, the court believed the
resolution of that issue would aid its consideration of the second question-
-whether the plaintiffs sufficiently alleged an "antitrust injury."
104
The court first looked to Supreme Court precedent regarding the rel-
evant antitrust law to determine the scope of the rule of reason and the
requirements for properly applying the per se illegality approach. 10 5 The
court recognized that a literal reading of the Sherman Act would lead to
the conclusion that all agreements that restrain trade are illegal, but that
the Supreme Court has interpreted the language of that act to prohibit
only unreasonable restraints.' 0 6 The rule of reason approach, as devel-
oped by the Supreme Court, requires the finder of fact to evaluate various
conditions, both pre- and post-restraint, to determine whether the poten-
tial procompetitive effects of the restraint outweigh its harmful effects.
10 7
The court found that the per se approach was to be applied when a court
could predict, from experience, that a particular type of restraint would
almost always be condemned under the rule of reason.10 8 The two signifi-
100. See id. ("Some types of restraints, however, ... are deemed unlawful per
se.").
101. Id. at 907-08 (deciding first to address whether Agreement was per se ille-
gal restraint of trade and listing pertinent facts of Agreement that demonstrated
per se illegality).
102. See id. at 900 (reciting certified questions).
103. See 28 U.S.C. § 1292(b) (2000) (granting district court permission to cer-
tify to circuit court controlling questions of law to which there is substantial
ground for difference of opinion).
104. See Cardizem CD Ii, 332 F.3d at 906 (expressing belief that whether
Agreement was per se illegal would "shed light" on adequacy of alleged antitrust
violation). The allegations of antitrust injury are outside the scope of this Note
and will not be addressed.
105. See id. at 906-07 (analyzing Sherman Act line of cases to determine rele-
vant applications of antitrust law, focusing on rule of reason analysis versus per se
illegality analysis).
106. See id. at 906.
107. See id. (citing Arizona v. Maricopa County Medical Society, 457 U.S. 332, 342
(1982), which described rule of reason approach). In Maricopa County, Justice Ste-
vens wrote:
Under [a rule of reason] approach, the "finder of fact must decide
whether the questioned practice imposes an unreasonable restraint on
competition, taking into account a variety of factors, including specific
information about the relevant business, its condition before and after
the restraint was imposed, and the restraint's history, nature, and effect."
457 U.S. 332 at 342.
108. See Cardizem CD III, 332 F.3d at 906 (examining Supreme Court decisions
applying per se analysis and finding language indicating its appropriateness only
17
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cant consequences of applying a per se approach are a conclusive presump-
tion of illegality to the restraint, barring the defendant from raising any
procompetitive justifications,10 9 and the ability of the court to conclude
that a restraint, which may otherwise be permitted under a rule of reason
analysis, is illegal. 110 The court then identified certain types of restraints
the Supreme Court has held to be subject to a per se rule, including "hori-
zontal restraints pertaining to prices.""1 The court, further using Su-
preme Court language, stated that the classic example1 12 of a per se
restraint is between competitors at the same level of the market that agree
to allocate the market in order to reduce competition.
113
The court applied its analysis of the relevant antitrust law to the terms
of the Agreement and concluded that it was a horizontal agreement to
remove competition in the Cardizem CD market.' 14 The court made the
following findings: (1) Andrx was Hoechst's only competitor at the time of
the Agreement; 115 (2) Hoechst and Andrx agreed on $10 million pay-
ments per quarter from Hoechst to Andrx, and, in return, Andrx would
refrain from marketing its generic version of Cardizem CD, even after re-
ceiving FDA approval;1 16 (3) from July 1998 until June 1999, Andrx did
not market its generic version of the drug, and Hoechst paid Andrx $89.83
million during that same period;1 17 (4) by delaying entry into the market,
Andrx prevented the start of its 180-day exclusivity period, which kept all
other potential generic competitors out of the market; 1 8 and (5) the
where court has experience predicting activity's anticompetitive effects); In re
Cardizem CD Antitrust Litig. (Cardizem CD II), 105 F. Supp. 2d 682, 694 (E.D.
Mich. 2000) (finding Sixth Circuit's application of per se analysis only where prior
cases have established anticompetitive effects of sufficiently similar business
practice).
109. See Cardizem CD III, 332 F.3d at 906 (reciting Supreme Court holding that
where per se analysis applies, there will be no analysis of procompetitive justifica-
tions); Cardizem CD II, 105 F. Supp. 2d at 693 (concluding that once restraint is
deemed per se illegal, no further inquiries into merits of restraint are warranted).
110. See Cardizem CDIII, 332 F.3d at 906 n.ll (citing Maricopa County, 457 U.S.
at 344; United States v. Topco Assocs., Inc., 405 U.S. 596, 609 (1972)). The
Cardizem CD III court noted: "The risk that the application of a per se rule will lead
to the condemnation of an agreement that a rule of reason analysis would permit
has been recognized and tolerated as a necessary cost of this approach."
111. Id. at 907.
112. See id.
113. See id. (citing Topco, 405 U.S. at 608, which explained horizontal restraint
as agreement between competitors at same level who allocate territories to mini-
mize competition); Cardizem CD II, 105 F. Supp. 2d at 694 (noting similar language
in Sixth Circuit opinion Betkerur v. Aultman Hospital Ass'n, 78 F.3d 1079, 1088 (6th
Cir. 1996)).
114. See Cardizem CD Il, 332 F.3d at 908 (noting core of Agreement between
Andrx and Hoechst entailed classic horizontal agreement to eliminate
competition).
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Agreement resulted in the protection of Hoechst's exclusive access to the
U.S. market until the end date contemplated by both parties.1 19 The
court concluded: "There is simply no escaping the conclusion that the
Agreement... was, at its core, a horizontal agreement to eliminate com-
petition .... a classic example of a per se illegal restraint of trade."
1 20
Following its determination that the Agreement constituted a hori-
zontal market allocation between competitors, the court analyzed the de-
fendants' arguments against the per se determination and found none of
them persuasive.1 2 1 The defendants submitted a multitude of arguments
to the district court in an attempt to avoid the determination that the
Agreement was a per se illegal restraint of trade;122 however, the circuit
court addressed only three of those arguments, referring instead to the
district court's analysis regarding the others.1 23 First, the defendants char-
acterized the Agreement as an attempt to enforce patent rights or, alterna-
tively, as an interim settlement.1 24 While the court agreed that federal law
permits one to take advantage of a monopoly that occurs as a result of
rights accruing under a patent, it regarded this characterization as merit-
less. 125 The court argued that the Agreement went beyond the specific
patent at issue in the litigation and encompassed all of Andrx's products
that were potential bioequivalents to Cardizem CD. 126 Second, the de-
119. See id.
120. Id. at 908.
121. See id.
122. See In re Cardizem CD Antitrust Litig. (Cardizem CD II), 105 F. Supp. 2d
682, 694-95 (E.D. Mich. 2000) (reciting arguments defendants intended to make
avoiding per se treatment). At trial, the defendants asserted the following argu-
ments: (1) Hoechst and Andrx were neither horizontal nor potential horizontal
competitors as the terms are defined; (2) the Agreement was not an attempt to
allocate markets or fix prices; (3) the Agreement was reasonably ancillary to
procompetitive activity, not a "naked" restraint of trade; (4) the Agreement should
be viewed as analogous to a patent settlement and, thus, analyzed under the rule of
reason; and (5) the Agreement is immune from antitrust scrutiny under the Noerr-
Pennington doctrine. See id.
123. See Cardizem CD III, 332 F.3d at 908 (citing district court opinion for
greater analysis with respect to finding defendants' arguments for avoiding per se
analysis unpersuasive). Interestingly, the circuit court allocated only one page of
its opinion to addressing the defendants' arguments for avoiding per se treatment,
whereas the district court spent seven pages addressing the same topic. Compare
Cardizem CD Ill, 332 F.3d at 908-09, with Cardizem CD II, 105 F. Supp. 2d at 700-06.
124. See Cardizem CD 11I, 332 F.3d at 908.
125. See id. (describing defendants' arguments as unpersuasive and noting
that Agreement bolstered patent's effectiveness).
126. See id. at 908 n.13 (citing In re Ciprofloxacin Hydrochloride Antitrust
Litig. (Cipro), 261 F. Supp. 2d 188, 242 (E.D.N.Y. 2003)). In Cipro, the court
stated:
[Wihen the Cardizem court condemned the HMR [Hoechst]/Andrx
agreement, it emphasized that the agreement restrained Andrx from
marketing other bioequivalent or generic versions of Cardizem that were
not at issue in the pending [patent] litigation .... Thus, the court found
that the agreement's restrictions extended to noninfringing and/or po-
tentially noninfringing versions of generic Cardizem.
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fendants claimed that the novelty of this area of law precluded a designa-
tion of per se illegality. 127 The court also regarded this argument as
without merit, relying on the Supreme Court's previous holding that the
Sherman Act "establishes one uniform rule applicable to all industries
alike."'128 Finally, the defendants asserted that the per se designation was
inapplicable because the Agreement was, in fact, not anticompetitive and
actually contained procompetitive benefits. 129 The court referred to the
defendants' argument as "simply irrelevant"' 30 because the per se designa-
tion forecloses the defendants' opportunity to raise any procompetitive
justifications. 1
3
C. Critical Analysis-Rule of Reason Approach?
While the Sixth Circuit may have correctly characterized the Agree-
ment as an illegal restraint of trade under the Sherman Act, the court
improperly designated the Agreement per se illegal instead of applying the
more commonly used rule of reason analysis. 132 In fact, in reference to
the Cardizem CD II decision and others like it, the chairman of the ABA
Antitrust Section, Intellectual Property Division stated that cases applying
the per se designation should not be "overread."'13 3 A more considered
261 F. Supp. at 242.
127. See Cardizem CD III, 332 F.3d at 908.
128. Id. (citing United States v. Socony-Vacuum Oil, 310 U.S. 150, 222
(1940)).
129. See id. at 908-09.
130. See id. at 909.
131. See id. (citing Arizona v. Maricopa County Med. Soc'y, 457 U.S. 332, 351
(1982)). The Cardizem CD IXl court stated:
The respondents' principal argument is that the per se rule is inapplicable
because their agreements are alleged to have procompetitive justifica-
tions. The argument indicates a misunderstanding of the per se concept.
The anticompetitive potential inherent in all price-fixing agreementsjus-
tifies their facial invalidation even if procompetitive justifications are of-
fered for some. Those claims of enhanced competition are so unlikely to
prove significant in any particular case that we adhere to the rule of law
that is justified in its general application.
Id.
132. See State Oil Co. v. Khan, 522 U.S. 3, 21 (1997) (noting that per seapplica-
tion cannot remain static but must change to accommodate agreements made in
varying circumstances and times); Cipro, 261 F. Supp. 2d at 232-33 (noting that
while there is facial appeal in applying per se treatment, circumstances surrounding
these types of agreements pose obstacle to its use); HOVENKAMP, supra note 8,
§ 5.6b, at 253 ("Because per se rules are empirical judgments, their fate is to go
through a continual evolutionary process."); Morse, supra note 2, at 361, 367, 373
(stating necessity of applying rule of reason analysis in all patent settlement cases
because difficulty of analyzing patent issues should caution courts away from facial
appeal of per se analysis and noting further that it is appropriate for all courts deal-
ing with patent settlements to adopt bright line policy of rule of reason analysis to
all patent settlement cases).
133. See Morse, supra note 2, at 399 (discussing effect of per se label on analysis
of these cases).
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approach, using the rule of reason, would not have eliminated a future
determination concerning the alleged illegality of the Agreement.
1 3 4
Moreover, such an approach would have allowed the court to conclude
that the defendants engaged in an illegal restraint of trade without fore-
closing consideration of key factors necessary to evaluate the Agreement
fully.
13 5
Policy considerations-primarily the ongoing debate about prescrip-
tion drugs and how much protection should be afforded the consumer
versus the innovator-also dictate a more cautious approach to patent set-
tlement arrangements between pioneer and generic drug companies.
136
Additionally, the court's analysis of the relevant Supreme Court antitrust
holdings regarding the proper application of a per se designation failed to
elaborate on other key aspects of those rulings, casting doubt upon the
soundness of the court's approach.137 Finally, in In re Ciproflaxcin Hydro-
chloride Antitrust Litigation ("Ciprd'),138 a similar case decided in the period
between Cardizem CD II and Cardizem CD III, the court sought to distance
itself from the analysis employed in Cardizem CD II, which the Cardizem CD
III court supported and upheld.139 Ironically, the Cardizem CD III court
actually cited Cipro as support for its per se application.
140
1. Rule of Reason Does Not Confer Legality
A finding by the court that the Agreement would be analyzed under
the rule of reason would not have foreclosed the possibility of concluding
that the Agreement was an illegal restraint of trade under the Sherman
Act. Indeed, those courts and commentators who have evaluated the
Agreement have stated that the Agreement was likely an illegal restraint of
trade.1 4' The Supreme Court and other courts, however, have made it
134. For a discussion of the rule of reason approach, see infra notes 141-43
and accompanying text (stating generally that rule of reason determinations do
not lend presumption of legality to arrangement, nor do they foreclose opportu-
nity to condemn arrangement at later date).
135. For a complete discussion surrounding the consequences of a rule of
reason designation, see infra notes 141-43 and accompanying text.
136. For a complete discussion of the policy implications contradicting the
court's analysis, see infra notes 185-99 and accompanying text.
137. For a complete discussion on the court's misinterpretation of Supreme
Court precedent, see infra notes 167-84 and accompanying text.
138. 261 F. Supp. 2d 188 (E.D.N.Y. 2003).
139. See In re Cardizem CD Antitrust Litig. (Cardizem CD III), 332 F.3d 896,
900 (6th Cir. 2003) (affirming Cardizem CDI Hgrant of summary judgment because
Agreement was per se illegal).
140. See id. at 908 n.12, 909 n.13 (citing Cipro in support of per se illegal find-
ing on basis that Agreement went beyond bounds of patent protection and en-
couraged continuing litigation).
141. See Cipro, 261 F. Supp. 2d at 242 (discussing negative impact on generic
drug trade resulting from settlement agreements); see also Morse, supra note 2, at
399-401 (stating generally that Cardizem CD II holding should be read to condemn
interim settlement agreements that do not fully resolve pending patent litigation).
In Cipro, the district court noted that:
2004] NOTE
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clear that a per se determination is not necessary solely for the purpose of
condemning an arrangement; moreover, an arrangement analyzed under
the rule of reason is not given a presumption of legality. 1 42 Therefore,
while the court may have been predisposed to the "illegality" of the Agree-
ment, it did not need to make a finding of per se illegality at the summary
judgment stage in order to condemn the Agreement.
143
2. In re Ciprofloxacin Hydrochloride Antitrust Litigation ("Cipro")
The court in Cipro dealt with a factual situation similar to that
presented in Cardizem CD Litigation.144 As in Cardizem CD Litigation, the
[In the Cardizem and Terazosin cases,] the brand-name drug manufactur-
ers entered into agreements with prospective generic competitors on the
verge of commencing marketing in exchange for the generic manufac-
turer's agreement to stay off the market pending the outcome of the pat-
ent litigation. This fact, in connection with the agreements' other
restraints, underscores the anticompetitive nature of the agreements ....
261 F. Supp. 2d at 242 (emphasis added).
142. See State Oil Co. v. Khan, 522 U.S. 3, 22 (1997) (overruling prior case
that found vertical maximum price fixing to be per se illegal); Nat'l Collegiate Ath-
letic Ass'n v. Bd. of Regents of the Univ. of Okla., 468 U.S. 85, 104-05 (1984) (hold-
ing that NCAA control over televising college football contests was restraint on
price and output likely to have anticompetitive effect, but finding it per se illegal
was not necessary); Cipro, 261 F. Supp. 2d at 257-58 (stating that decision does not
conclusively determine legality of agreements rendering them "not subject to fur-
ther scrutiny" because "plaintiffs [could] show that the challenged agreements are
unreasonable restraints of trade under the rule of reason"); see also HOVENKAMP,
supra note 8, § 5.6b, at 253 ("As the development of [Supreme Court] cases sug-
gests, the most difficult aspect of the jurisprudence of the per se rule is determining
when it should be followed."). In State Oi4 the Court noted that in overruling the
per se unlawfulness of the action, it was not finding it "per se lawful." 522 U.S. at 22.
Rather, the Court stated the action belonged with the majority of commercial ac-
tivities, properly relegated to a rule of reason analysis, which will "effectively iden-
tify" situations that amount to anticompetitive conduct. See id. Prior to State Oil,
the Court stated in NCAA: "The fact that a practice is not categorically unlawful in
all or most of its manifestations certainly does not mean that it is universally law-
ful .... The essential point is that the rule of reason can sometimes be applied in
the twinkling of an eye." 468 U.S. at 109 n.39 (citation omitted).
143. See Cipro, 261 F. Supp. 2d at 257 ("At this early juncture, this case should
not be relegated to the per se category reserved for the most blatant antitrust
violations.").
144. See id. at 194-97 (stating factual background involving agreement be-
tween Bayer and generics). Barr Laboratories, Inc. ("Barr"), a generic drug manu-
facturer, filed a Paragraph IV certification in an ANDA for Cipro on October 22,
1991, and notified Bayer on December 6, 1991. See id. at 194. Bayer sued Barr for
patent infringement on January 16, 1992, and in November 1992, both parties
agreed to extend the thirty-month stay until patent litigation was resolved. See id.
at 194-95. While waiting for the trial to commence, Barr entered into agreements
with Hoechst, The Rugby Group, Inc. ("Rugby") and Watson Pharmaceuticals, Inc.
("Watson") concerning the eventual production and marketing of generic Cipro.
See id. at 195. Just prior to the trial, Bayer and Barr settled their patent dispute,
and, subsequently, all four parties entered into a supply agreement and a settle-
ment agreement along with some other ancillary parties. See id. at 195-96. Essen-
tially, the agreements barred the generics from manufacturing Cipro until either
Bayer's patent on Cipro expired or another party successfully challenged the Cipro
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plaintiffs in Cipro comprised a class of direct and indirect purchasers of
Cipro as well as individual non-class plaintiffs.1 4 5 Defendants were a
brand-name manufacturer, Bayer, and a collection of generic manufactur-
ers. 146 The plaintiffs alleged that the drug manufacturers entered into
agreements to prevent competition for Cipro in violation of federal and
state antitrust laws. 14 7 While the court in Cardizem CD X11 summarily dis-
missed defendants' arguments against per se designation148-namely, that
the Act's scheme created a "novel" area of law, 149 that the Agreement was
an attempt to enforce patent rights150 and that the Agreement was an in-
terim settlement 15 1-the Cipro court thoroughly analyzed all three is-
sues, 152  concluding that these circumstances "pose significant
obstacles"1 5 3 to designating an agreement in this area as deserving of per se
treatment.
patent. See id. at 196. In the interim, Bayer agreed to supply Barr with Cipro for
marketing under a generic name or, alternatively, to make quarterly payments of
approximately $16 million to the generics. See id. Since the agreement's incep-
tion, through December 2003, Bayer has paid nearly $400 million to the generics.
See id. While the parties submitted a consent decree to the judge indicating their
resolution of the patent litigation, the consent decree lacked information concern-
ing Bayer's payment to the generics and the arrangement of payments in lieu of
supplying Cipro. See id. at 196-97.
145. Compare id. at 191 (describing plaintiffs involved in litigation), with In re
Cardizem CD Antitrust Litig. (Cardizem CD I), 105 F. Supp. 2d 618, 625-27 (E.D.
Mich. 2000) (describing plaintiffs involved in litigation).
146. Compare Cipro, 261 F. Supp. 2d at 191, with In re Cardizem CD Antitrust
Litig. (Cardizem CD III), 332 F.3d 896, 899 (6th Cir. 2003) (demonstrating de-
fendants are in similar market positions in both cases, namely, brand-name defen-
dant and generic manufacturer defendant).
147. Compare Cipro, 261 F. Supp. 2d at 191-92, with Cardizem CDIII, 332 F.3d at
900, 904 (demonstrating plaintiffs in both cases allege violation of state and fed-
eral antitrust laws).
148. For a complete discussion on the arguments presented to the Cardizem
CD III court, see supra notes 121-31 and accompanying text.
149. See Cardizem CD 111, 332 F.3d at 908.
150. See id.
151. See id.
152. See Cipro, 261 F. Supp. 2d at 233-34 (outlining court's rationale in decid-
ing relevant factors in determining whether to apply rule of reason or per se treat-
ment to agreements). The court stated:
This case involves the rights of a patent holder whose patent ... has never
been found invalid. This case also involves the Hatch-Waxman Amend-
ments-a new statutory scheme creating a novel, low-cost method for
challenging the validity of drug patents. Lastly, this case involves settle-
ment agreements, the type of agreements, generally speaking, en-
couraged by the legal system and entered into with great frequency.
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Unlike the Cardizem CD Litigation courts that dismissed the effects that
a valid patent imposes on evaluating anticompetitive effects, 154 the court
in Cipro evaluated the rights granted to a patent holder under the law and
their implications with respect to alleged antitrust violations. 15 5 In its eval-
uation, the Cipro court concluded, as a matter of law, that the proper
course of action entails an analysis of the exclusionary effects of a valid
patent prior to a determination of the propriety of designating an agree-
ment per se illegal. 15 6 The Cipro court was highly critical of the analysis
used by the court in Cardizem CD II, going so far as to comment: "It is fairly
evident that the district court[ I in Cardizem... did not employ this analysis
and, instead, immediately labeled the challenged restraint [a] per se illegal
horizontal market allocation agreement[ ].157
The Cipro court then examined the effect the Act had on settlements
in patent litigation, 15 8 holding that the Act created a unique situation
where reverse payments-which are normally condemned-are actually a
"natural by-product" of its statutory scheme. 159 This holding was in direct
contrast to Cardizem CD II, which condemned the Agreement's reverse
154. Compare id. at 247-49 (analyzing effects of patent protections as they re-
late to antitrust violations), with In re Cardizem CD Antitrust Litig. (Cardizem CD
II), 105 F. Supp. 2d 682, 701 (E.D. Mich. 2000) (failing to address patent issue),
and Cardizem CD II, 332 F.3d at 908 (agreeing with Cardizem CD II conclusion,
which found unpersuasive defendants' argument that patent rights avoid per se
treatment). In a twenty-four-page opinion, the district court in Cardizem CD II de-
voted one sentence to analyzing the impact of Hoechst's patent: "The anti-compet-
itive effects of [Hoechst's] patent are ... not at issue." Cardizem CD II, 105 F. Supp.
2d at 701. Amazingly, the Sixth Circuit actually said: "As can be explained in greater
detail in the district court's opinion, ... the Agreement cannot be fairly character-
ized as merely an attempt to enforce patent rights ...." Id. (emphasis added).
This lack of analysis was one of the reasons the Cipro court declined to follow
Cardizem CD II. See Cipro, 261 F. Supp. 2d at 247 ("Accordingly, this court de-
clines ... to follow the reasoning in Cardizem ... and to find the [agreements] in
this case per se illegal without a more elaborate inquiry into the effects of Bayer's
patent monopoly on the conduct at issue.").
155. See Cipro, 261 F. Supp. 2d at 248-49 (examining development of law with
respect to exclusion rights of patent holder and implication in antitrust context
and finding scope of patent protection must be examined); see also HOVENKAMP,
supra note 8, § 5.6b, at 252 (examining different scenarios requiring rule of reason
versus per se treatment and concluding alleged monopolization involving innova-
tion policies of firm would require rule of reason analysis).
156. See Cipro, 261 F. Supp. 2d at 249 (stating proper analysis where patent is
at issue). The court stated:
Accordingly, when patents are involved, case law directs that the exclu-
sionary effect of the patent must be considered before making any deter-
mination as to whether the alleged restraint is per se illegal. Therefore,
the proper analysis in this case is whether the plaintiffs have proven as a
matter of law that the challenged agreements restrict competition beyond
the exclusionary effects of the [patent].
Id.
157. Id. at 249 n.62 (emphasis added).
158. See id. at 249-52 (examining settlement agreements in context of Act's
statutory scheme).
159. See id. at 252 (stating effect of Act on settlements). The court stated:
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structure of settlement payments, 160 and Cardizem CD III, which held that
per se treatment applied despite the novelty of the Act.16 1 The court in
Cipro looked to the normal state of affairs for entering a market controlled
by a patent holder and found that in a traditional patent settlement scena-
rio consideration would flow from the generic manufacturer to the patent
holder. 162 Under the Act, however, the court noted that the normal cost
and risk assessments of the parties are drastically changed,1 6 3 and the re-
sult is that "consideration flows from the patent owner . . . to the chal-
lenger . . .and not vice versa, as in a traditional context."1 64 The Cipro
court held that because of the statutory scheme of the Act, a per se condem-
[B]ecause of the generic manufacturer's entitlement under the Hatch-
Waxman Amendments to institute patent litigation merely by filing an
ANDA IV, the statutory scheme has the unintended consequence of alter-
ing the litigation risks of patent lawsuits. Accordingly, so-called reverse
payments are a natural by-product of the Hatch-Waxman process ....
Id.
160. See In re Cardizem CD Antitrust Litig. (Cardizem CD II), 105 F. Supp. 2d
682, 704 n.14 (E.D. Mich. 2000) ("'If the patent owner pays the infringer, and if
the infringer settles by ... agree[ing] to abandon the field, scrutiny is war-
ranted.'") (quoting RobertJ. Hoerner, Antitrust Pitfalls in Patent Litigation Settlement
Agreements, 8 FED. CIR. B.J. 113, 123 (1998)) (alteration and omission added).
161. See In re Cardizem CD Antitrust Litig. (Cardizem CD III), 332 F.3d 896,
908 (6th Cir. 2003) (holding novelty does not preclude per se application). The
court stated:
Nor does the fact that this is a "novel" area of law preclude per se treat-
ment. To the contrary, the Supreme Court has held that "whatever may
be its peculiar problems and characteristics, the Sherman Act, so far as
price-fixing agreements are concerned, establishes one uniform rule ap-
plicable to all industries alike."
Id. (internal citations omitted).
162. See Cipro, 261 F. Supp. 2d at 251 (explaining general situation involving
one party attempting to enter market protected by patent). The court essentially
stated that to enter a protected drug market in a non-Act situation, a generic com-
pany would incur costs of research, manufacturing and marketing. See id. Once
the drug is on the market, the patent holder's sales would have dropped, and it is
likely the patent holder would sue for lost profits and willful infringement. See id.
The court found that a settlement between the two, assuming a valid patent, would
result in money flowing from the generic manufacturer to the patent holder. See
id.
163. See id. (noting how Act distorts commonly held legal principles regarding
settlements). The court stated:
By contrast, in creating an artificial act of infringement (the ANDA IV
filing), the Hatch-Waxman Amendments grant generic manufacturers
standing to mount a validity challenge without incurring the cost of entry
or risking enormous damages flowing from infringing commercial sales.
This statutory scheme affects the parties' relative risk assessments and ex-
plains the flow of settlement funds and their magnitude. Because of the
Hatch-Waxman scheme, Barr's exposure in the patent litigation was lim-
ited to litigation costs, but its upside-exclusive generic sales-was im-
mense. The patent holder, however, has no corresponding upside, as
there are no infringement damages to collect, but an enormous down-
side-losing its patent.
164. Id. at 251-52.
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nation of reverse payments in a patent settlement context was not appro-
priate, 165 contrary to the determinations made in Cardizem CO 11 and
Cardizem CD 111.166
3. Uneven Application of Supreme Court Precedent: Absence of Key Factors
The Cardizem CD III court's analysis of Supreme Court precedent,
16 7
guiding its decision to find the Agreement per se illegal, failed to apply the
rationale behind the High Court's holdings. Specifically, the court failed
to take into account the FTC's findings on the Agreement and the "nov-
elty" of the Act in relation to whether the court had the necessary experi-
ence to conclusively determine the Agreement was per se invalid.
The court cited Broadcast Music, Inc. v. Columbia Broadcast System,
Inc.168 for support in applying a per se rule to the Agreement. 1 69 Dealing
with a copyright antitrust claim in that case, the Supreme Court stated that
although it was not bound by an executive agency determination, 170 and a
favorable agency determination would not necessarily immunize defend-
ants from private action,1 71 courts must take into account the fact that an
165. See id. at 252 (stating that because of Act's process, reverse payments pre-
sent in agreement are not so nefarious as to warrant per se treatment).
166. See Cardizem CD III, 332 F.3d at 915 (affirming both district court's denial
of motion to dismiss by defendants and grant of partial summary judgment to
plaintiffs because Agreement constituted per se illegal violation of Sherman Act); In
re Cardizem CD Antitrust Litig. (Cardizem CD II), 105 F. Supp. 2d 682, 706-07
(E.D. Mich. 2000) (granting plaintiffs' motion for partial summary judgment be-
cause Agreement constituted per se illegal violation of Sherman Act).
167. See Cardizem CD Il, 332 F.3d at 906-09 (citing Arizona v. Maricopa County
Medical Society, 457 U.S. 332 (1982), nine times where Court, by 4-3 vote, con-
demned maximum price-fixing arrangement by group of doctors as per se illegal);
id. at 906 (citing State Oil Co. v. Khan, 522 U.S. 3 (1997), three times where Court,
by unanimous decision, held that vertical price-fixing arrangements are not per se
illegal); id. at 906-07 (citing National Collegiate Athletic Ass'n v. Board of Regents of the
University of Oklahoma, 468 U.S. 85 (1984), two times where Court, by 7-2 vote, held
that NCAA had unreasonably restrained trade, but that its actions were not subject
to per se rule); id. at 907 (citing United States v. Topco Associates, Inc., 405 U.S. 596
(1972), two times where Court, by 6-1 margin with Justice Blackmun concurring,
condemned arrangement between cooperative of small grocery stores as per se ille-
gal); id. at 906 (citing Broadcast Music, Inc. v. Columbia Broadcasting System, Inc., 441
U.S. 1 (1979), where Court, by 8-1 vote, found that blanket copyright licensing
arrangement was not subject to per se rule, nor was it illegal restraint of trade).
168. 441 U.S. 1 (1979).
169. See Cardizem CD III, 332 F.3d at 906 ("[A] perse rule is applied when 'the
practice facially appears to be one that would always or almost always tend to re-
strict competition and decrease output.'") (quoting Broad. Music, 441 U.S. at 19-
20).
170. See Broad. Music, 441 U.S. at 16 (stating Supreme Court is not bound by
views of DOJ).
171. See id. at 13 ("[A] consent judgment, even one entered at the behest of
the Antitrust Division, does not immunize the defendant from liability for actions,
including those contemplated by the decree, that violate the rights of
nonparties.").
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executive agency scrutinized the arrangement. 172 The alternative, noted
the Court, would be that an "unthinking application of the per se rule
might upset the balancing of economic power and of procompetitive and
anticompetitive effects presumably worked out in the decree" between the
defendants and the executive agency.
173
On March 16, 2000, the FTC filed a complaint against Hoechst and
Andrx. 174 The complaint alleged that the Agreement was an unreasona-
ble restraint of trade,' 75 The Cardizem CD II decision filed on June 6,
2000, examined the FTC complaint; however, because the administrative
hearing was set for November 14, 2000, the court was unable to signifi-
candy evaluate its impact.' 7 6 On April 2, 2001, the FTC, Hoechst and
Andrx entered into a consent agreement.' 77 The Sixth Circuit decided
Cardizem CD IX on June 13, 2003, over two years after the FTC consent
decree, yet not a single mention of the decree appears in the court's opin-
ion. 178 Significantly, the FTC stated:
Based on the FTC's investigation, it does not appear that there
was any delay in the entry into the market of a generic version of
Cardizem CD by Andrx or any other potential manufacturer, or
that the conduct or agreement at issue delayed consumer access
to a generic version of Cardizem CD. 179
It is difficult to rationalize the court's application of the per se rule in light
of the Supreme Court's instruction to examine agency determinations, es-
172. See id. ("[I]t cannot be ignored that the Federal Executive and Judiciary
have carefully scrutinized ASCAP and the challenged conduct. . . [T] he decree
is a fact of economic and legal life in this industry, and the Court of Appeals should
not have ignored it completely in analyzing the practice.") (emphasis added).
173. Id. at 13 n.24.
174. See Complaint of FTC, In re Hoechst Marion Roussel, Inc., No. 9293,
2000 WL 288452 (F.T.C. Mar. 16, 2000), available at http://www.ftc.gov/os/2000/
03/hoechstandrxcomplaint.htm [hereinafter FTC Complaint].
175. See FTC Complaint 29. Although the FTC alleged illegal restraint of
trade in violation of only 15 U.S.C. § 45, the Federal Trade Commission Act, the
Supreme Court has stated "the FTC Act's prohibition of unfair competition and
deceptive acts or practices . . . overlaps the scope of § 1 of the Sherman Act...
aimed at prohibiting restraint of trade." Cal. Dental Ass'n v. FTC, 526 U.S. 756,
763 n.3 (1999).
176. See In re Cardizem CD Antitrust Litig. (Cardizem CD II), 105 F. Supp. 2d
682, 690 (E.D. Mich. 2000) (stating general allegations of FTC complaint and not-
ing hearing date of November 14, 2000).
177. See In re Hoechst Marion Roussel, Inc., No. 9293, 2001 WL 333643
(F.T.C. Apr. 2, 2001) (decision and order), available at http://www.ftc.gov/os/
2001/04/hoechstdo.pdf [hereinafter FTC Consent Decree].
178. See In re Cardizem CD Antitrust Litig. (Cardizem CD III), 332 F.3d 896,
901-09 (6th Cir. 2003) (lacking any mention of FTC complaint or FTC consent
decree in both recitation of facts and legal analysis).
179. Hoechst Marion Roussel, Inc., 66 Fed. Reg. 18,636 (FTC Apr. 10, 2001),
available at http://www.ftc.gov/os/2001/04/hoechstanalysis.pdf. (providing analy-
sis to aid public comment).
2004] NOTE 617
27
King: Don't Bite the Hand That Provides Life-Saving Drugs: Application
Published by Villanova University Charles Widger School of Law Digital Repository, 2004
VIt.LANOVA LAW REVIEW
pecially considering this particular determination found no delay in ge-
neric entry to the Cardizem CD market.
8 0
Finally, while the court determined it apparently had the "considera-
ble experience" required by the Supreme Court to properly characterize
the Agreement as per se illegal, it is unclear that that determination was
accurate.' 8' First, the Supreme Court itself, in a unanimous decision in
Broadcast Music, held that it did not have the experience necessary in copy-
right law to find a per se rule applicable in the area of blanket licensing.
182
Second, the court in Cipro, facing a situation identical to Cardizem CD III,
undertook a detailed analysis of the rights of patent holders1 8 3 and the
interactions of parties within the Act,' 8 4 rather than concluding with cur-
sory analysis that a per se designation was warranted.
IV. STRONG PRO-INNOVATION POLICY NEEDED
Consumers and innovators both deserve proper protection; the diffi-
cult issue is striking a balance that spurs competition in the marketplace
while encouraging continued investment in innovation. 18 5 Recently, how-
ever, consumer protection has come at the expense of the innovator, par-
ticularly in the pharmaceutical industry.
186
Opponents of "big-pharma" frequently cite high prices for brand-
name drugs, upward increases in the percentage of health care costs spent
on drugs and large industry bottom lines as evidence of an industry with a
180. Compare Morse, supra note 2, at 392 ("If [the FTC found] no delay in
entry by either Andrx or any other potential manufacturer, it is difficult to under-
stand how the agreement diminished competition."), with Cardizem CD III, 332 F.3d
at 907 ("By delaying Andrx's entry into the market, the Agreement also delayed
the entry of other generic competitors, who could not enter until the expiration of
Andrx's 180-day period of marketing exclusivity ....").
181. Compare Arizona v. Maricopa County Med. Soc'y, 457 U.S. 332, 344
(1982) ("Once experience with a particular kind of restraint enables the Court to
predict with confidence that the rule of reason will condemn it, it has applied a
conclusive presumption that the restraint is unreasonable."), with United States v.
Topco Assocs., Inc., 405 U.S. 596, 607-08 (1972) ("It is only after considerable expe-
rience with certain business relationships that courts classify them as per se viola-
tions of the Sherman Act.") (emphasis added).
182. See Broad. Music, Inc. v. Columbia Broad. Sys., Inc., 441 U.S. 1, 9-10
(1979) (commenting on novelty of copyright and antitrust issue). The Court
stated: "We have never examined a practice like this one before; indeed, the Court
of Appeals recognized that '[i]n dealing with performing rights in the music indus-
try we confront conditions both in copyright law and in antitrust law which are sui
generis."' Id. at 10. (internal citations omitted).
183. See In re Ciprofloxacin Hydrochloride Antitrust Litig. (Cipro), 261 F.
Supp. 2d 188, 247-49 (E.D.N.Y. 2003) (analyzing federal law for effects of patent
law with respect to per se designation in antitrust law).
184. See id. at 250-52 (analyzing effect of "novel" statutory scheme in Act with
respect to antitrust condemnation of "reverse payments").
185. See Anthony, supra note 24, at 3, 37-38 (commenting on crucial balance
necessary for ensuring competitive market and protecting patent rights).
186. For a discussion on the impacts of congressional and FTC action towards
the pharmaceutical industry, see supra notes 1-2, 6-7 and accompanying text.
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monopolistic drive to maximize profits and stunt competition. 8 7 The
facts, however, indicate otherwise. Only about a dime out of every health
care dollar is spent on drugs, including generics) 88 Right now, the pro-
cess of bringing a drug to market costs $800 million and takes almost four-
teen years of testing and approval. 18 9 Out of five thousand potentially
viable compounds tested on animals, only five make it to the human
clinical testing stage, and of that five, only one makes it to market. 190
Once on the market, only about one out of five drugs will ever recoup its
initial investment and become profitable for a firm. 191 Pharmaceutical
companies also reinvest their profits into research and development more
187. See O'Reilly, supra note 1, at 430, 432 (providing political suggestion on
how Congress should handle lobbying effort of big pharmaceutical companies);
Generic Drugs, supra note 9, at 36 (providing economic overview of problems with
big-pharma); see also Lobanoff, supra note 2, at 1331, 1337-38 (claiming brand-
name pharmaceutical companies are only ones to blame for problems in Act).
Consumer Reports writes: "Protect the monopoly has become the innovators' man-
tra." Generic Drugs, supra note 9, at 36. The report continues to implicate big-
pharma, declaring: "Despite industry claims that it needs extraordinary profits to
finance risky, expensive research and development, the 11 companies in the For-
tune 500 spent just 12 percent of revenues on R&D and 30 percent on marketing
and administration; they took 17 percent as profits." Id. O'Reilly implicates Con-
gress as the primary source of the problem of prescription drug funding, stating:
"Instead of focusing on the pioneer drug industry's lucrative lobbying efforts,
Washington should turn its attention to the sick and elderly, whose funds pay for
prescription drugs." O'Reilly, supra note 1, at 432. O'Reilly goes on to state:
The principal sponsor of the [Act] criticized the "collusion" efforts of
pioneers, saying that it was "thoroughly at odds with the interests of
American consumers." . . . However, the amount of profits available
under the current scheme are so huge, that lobbyists for the innovative
companies oppose any changes to what was put in place seventeen years
earlier. These lobbyists still want more concessions from Congress,
Id. at 430.
188. See Alan F. Holmer, President & CEO, PhRMA, The Case for Innovation:
The Role of Intellectual Property, Address Before the Economist's Second Annual
Pharmaceuticals Roundtable (Nov. 20, 2002), available at http://www.phrma.org/
publications/publications/20.11.2002.629.cfm [hereinafter Holmer Speech]
("Prescription medicines make up about ten cents of each health care dollar.").
189. See JAMES W. HUGHES ET AL., NAT'L BUREAU OF ECON. RESEARCH, "NAP-
STERIZING" PHARMACEUTICALS: ACCESS, INNOVATION, AND CONSUMER WELFARE 7
(Oct. 2002), available at http://www.nber.org/papers/w9229 [hereinafter NBER
PAPER] ("The average drug takes twelve years to develop and test, with up to an
additional two years for FDA approval.").
190. See id. at 8.
191. See Nancy Duvergne Smith, Pharmaceutical Industry Balances High Profits,
Moral Ground, IMPACT (Winter 2003), at http://web.mit.edu/ctpid/www/im-
pactl llectures.html (last visited Apr. 6, 2004) (statement of Franz Humer, Chair-
man and CEO of Rouche Holding Ltd.) ("Of 10,000 compounds in the test tube,
only ten make it to human testing. Only one makes it to market. And only one of
four that make it to market returns its investment."); PhRMA, Fact Sheet: Pharmaceu-
tical Patent Incentives, at http://www.phrma.org/publications/publications/
17.06.2003.746.cfm (last visited Jan. 14, 2004) ("Seven out of every ten medicines
approved by FDA do not generate sufficient sales to cover average research and
development costs."); see also In re Ciprofloxacin Hydrochloride Antitrust Litig.
(Cipro), 261 F. Supp. 2d 188, 256 (E.D.N.Y. 2003) ("[O]nly 30% or less of mar-
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than all other industries combined-an estimated $32 billion alone in
2002.192 Additionally, drug consumers are not all being impacted to the
extent that is being reported. A study by the Agency for Healthcare Re-
search and Quality and the National Center for Health Statistics found
that the top twenty percent of all drug purchasers pay over eighty-six per-
cent of all drug costs. 19 3 Eighty percent of all drug purchasers in this
country spend, on average,just $66 on drugs per year, out of a total health
care budget of $1,160.194
Another issue that arises when discussing the need to protect consum-
ers is the definition of "consumer" and whether any duty is owed to the
future consumers and their right to receive life-saving drugs.1 95 A recent
paper by the National Bureau of Economic Research ("NBER Paper") has
shown that pharmaceutical patents have been considerably weakened,
with an effective market life of only 6.5 years. 19 6 Additionally, the NBER
Paper concluded that if the current trend of pharmaceutical patent ero-
sion continues in favor of consumer protection, this country will suffer a
future consumer loss of $3 for every $1 of current consumer gain by faster
generic entry into the market.1 97 Yet Congress and the FTC, rather than
keted drugs produce revenues that that equal or exceed their average R&D
costs.").
192. See PhRMA, Patent Incentives for Discovery of New Medicines Must Be Main-
tained, PhRMA Tells Lawmakers (June 17, 2003), at http://www.phrma.org/
mediaroom/press/releases/17.06.2003.747.cfm (noting organization's members
invested estimated $32 billion in research and development).
193. See PhRMA, Who Is Cared for with Prescription Medicines? Characteristics of
Individuals with High Prescription Drug Expenses in 2000 (Summer 2003), at http://
www.phrma.org/publications/twopager/2003-09-04.847.pdf (last visited Apr. 6,
2004) (citing data reported in 2000 Medical Expenditure Panel Survey).
194. See id.
195. See NBER PAPER, supra note 189, at 3-4 (stating policy implications of
result of study). The authors conclude that the "sub-optimal" patent protection
afforded pharmaceuticals is the result of public policies being influenced by con-
sumer groups that are identifiable and well organized. See id. Because of this influ-
ence, there is a risk that actual consumers of prescription drugs have a greater
voice in determining the public policy than the unknown potential consumer, who
is either waiting for a drug to be invented that is not yet on the market or has not
yet contracted the specific ailment requiring drug therapy. See id. at 4.
196. See id. at 5 (examining pharmaceutical patents and exclusivity periods
from 1997-2001 and finding average of 6.5 years in 2001).
197. See id. at Abstract (concluding weakened pharmaceutical patents result
in three dollars of future consumer loss for one dollar of present day gain). The
authors state:
We find that providing greater access to the current stock of prescription
drugs yields large benefits to existing consumers. However, realizing
those benefits has a substantially greater cost in terms of lost consumer
benefits from reductions in the flow of new drugs. Specifically, the model
yields the result that for every dollar in consumer benefit realized from
providing greater access to the current stock, future consumers would be
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strengthening pharmaceutical patent protection, have chosen to single
out the pharmaceutical patent and weaken it further with the short-
sighted goal of lowering current drug prices.19 8 If one considers the con-
sumer as a continuous entity, then the need for a strong pro-innovation
policy becomes self-evident; without such a policy, the future consumer
will suffer for the short-term benefit of the current consumer.'
99
V. CONCLUSION
In Cardizem CD III, the Sixth Circuit, apparently relying on Supreme
Court precedent condemning horizontal market allocations under the
Sherman Act, 200 characterized the Agreement as a per se illegal restraint of
trade.20 1 The court, however, did not analyze critical factors specific to
the Agreement within the context of the pharmaceutical industry, calling
into question whether the court had the "considerable experience" neces-
sary to make a per se determination and whether its holding should be
given any weight.20 2 Specifically, the court failed to address the FTC's
finding in its investigation of the Agreement, the effects of patent rights as
an exclusionary market force and the unique framework of the Act as it
pertains to settlement agreements in patent infringement actions.
20 3
While consumers deserve access to affordable health care and protection
from illegal antitrust conduct, both the courts and Congress need to come
to a more thorough understanding of the importance of the pharmaceuti-
cal industry in ensuring the health and well-being of current and future
198. For a discussion on the impacts of congressional and FTC action towards
the pharmaceutical industry, see supra notes 1-4, 6-7 and accompanying text.
199. See O'Reilly, supra note 1, at 415 (stating that patent protection must
remain strong for social benefit). O'Reilly states:
There is no dispute that innovators need to be able to recoup their invest-
ment at a profit, so that future financial investment in socially beneficial
pharmaceutical research will continue. Innovators in the pharmaceutical
field are bound by extremely complex and demanding controls estab-
lished for public protection. The "new drug application" process is re-
markably expensive and thorough, therefore the innovator's costs to be
recouped during the patent period include not only costs related to dis-
covery, but also the costs associated with regulatory approvals.
Id.
200. See In re Cardizem CD Antitrust Litig. (Cardizem CD IIl), 332 F.3d 896,
907 (6th Cir. 2003) (citing four Supreme Court cases for general proposition that
horizontal market allocations are naked restraints of trade and, thus, per se illegal).
201. See id. at 908 (holding Agreement was horizontal market allocation to
grant Hoechst entire U.S. market for diltiazem hydrochloride).
202. See Morse, supra note 2, at 399 (noting that Cardizem CD III holding
should not be "overread"). For a discussion and analysis of the use and application
of Supreme Court precedent by the Cardizem CD III decision, see supra notes 167-
84 and accompanying text.
203. For a complete analysis of the factors employed by the court in Cipro, as
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generations.20 4 If pharmaceutical companies are dissuaded from continu-
ing to invest in breakthrough drugs, ultimately the consumer suffers.
2 0 5
Moreover, if a constant production of breakthrough drugs is not main-
tained, the generic drug industry that will be left without a continuing
204. See In re Ciprofloxacin Hydrochloride Antitrust Litig. (Cipro), 261 F.
Supp. 2d 188, 256 (E.D.N.Y. 2003) (stating that policy favoring application of rule
of reason analysis over per se analysis encourages risk-taking and R&D investment).
The court stated:
[A] rule that makes it per se illegal to settle a Hatch-Waxman lawsuit...
limits the options available to both generic and brand-name manufactur-
ers. If brand-name manufacturers are unable to control or limit their risk
by settling Hatch-Waxman litigation, they, like generic manufacturers,
may be less inclined to invest the research and development ("R&D")
costs associated with bringing new drugs to market. The pharmaceutical
industry depends greatly on R&D and the economic returns to intellec-
tual property created when a successful new drug is brought to market. A
rule prohibiting settlements of Hatch-Waxman patent litigation can
have . . . extremely large effect[s] on the economic welfare and medical
well-being of US customers. The pharmaceutical industry in the US
spent $26 billion on R&D in 2000 with the average cost of developing a
new drug now estimated at $802 million. Yet only 30% (or less) of mar-
keted drugs produce revenues that equal or exceed their average R&D
costs. If incorrect judicial determinations are made that decrease the
value of the intellectual property, expected returns on R&D will decrease
and new drug innovation in the US will decrease. The results will be
fewer drugs that led in the past to healthier and more productive lives for
US customers and large gains to the US economy.
Although a policy in favor of settlement of litigation cannot save a
per se violation from the scriptures of the Sherman Act, a rule that too
quickly condemns actions as per se illegal, potentially chilling efforts to
research and develop new drugs and challenges the patents on brand-
name drugs, does competition-and thus, the Sherman Act-a disservice.
Application of the rule of reason will permit the court, in light of the
evidence presented by the parties, to balance the anticompetitive effects
of the [agreement] against the benefits of allowing brand-name drug
companies to invest in R&D with some degree of confidence that they will
be able to control patent litigation when they introduce new drugs. In
weighing these competing policy concerns under a rule of reason analy-
sis, the court will be able to take into account a variety of factors affecting
the degree of anticompetitive impact caused by the agreements.
Id. (internal citations omitted).
205. See Holmer Speech, supra note 188 (discussing importance of maintain-
ing strong incentives for discovering new medicines). Mr. Holmer first described a
scenario in 2050, where this country had strong patent protections for its drugs.
See id. In this scenario, life expectancy has increased and disability rates have
dropped. See id. Drug advances have made communicable diseases a thing of the
past; as a result, "[e]conomic productivity is up, sick days are on the decline, and
people [are] contribut[ing] to society well into their 80's." Id. This, he says, are
the human and economic realities of pharmaceutical patent protection. See id. In
scenario two, patent rights are weakened causing most pharmaceutical companies
to copy each other or older drugs. See id. Alzheimer's disease is rampant and
nursing homes are full, representing the fastest growing health care cost. See id. In
order to fund the exorbitant health care costs, Congress has "raised taxes and cut
funding to other programs." Id. Families are forced to expend large portions of
their budget caring for their sick or elderly parents and grandparents. See id. He
asks us to choose scenarios: "Where will you spend your 85th birthday?" Id.
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supply of pioneer drugs to copy and bring to market.20 6 The best way to
protect against these potential unfortunate happenings is to prevent the
erosion of patent rights for pharmaceutical companies and apply a rule of
reason analysis to agreements made within the pharmaceutical industry.
Edward j King
206. See NBER PAPER, supra note 189, at 19 (demonstrating graphically how,
when no new drugs are invented due to weakened patent rights, generic.manufac-
turers suffer loss of product to mimic).
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